hku.hk 参考文章(109)
Michael J Seckl, Rosemary A Fisher, Neil J Sebire, Gemma Petts, Dee Short, Ian Lindsay, Histopathological and immunohistochemical features of early hydatidiform mole in relation to subsequent development of persistent gestational trophoblastic disease. Journal of Reproductive Medicine. ,vol. 59, pp. 213- 220 ,(2014)
Fiorica Jv, Hoffman Ms, Robert Ws, Gleeson Nc, Finan Ma, Wilson J, Nonmetastatic gestational trophoblastic disease. Weekly methotrexate compared with 8-day methotrexate-folinic acid. European Journal of Gynaecological Oncology. ,vol. 14, pp. 461- ,(1993)
Michael J. Seckl, Rana Habbal, Ross S. Berkowitz, Donald P. Goldstein, Marilyn Bernstein, Barry Hancock, Jo Higgins, Brenda Kluhsman, Lari Wenzel, Sarah Strickland, Alanna Kulchak-Rahm, Edward Newlands, Quality of life after gestational trophoblastic disease Journal of Reproductive Medicine. ,vol. 47, pp. 387- 394 ,(2002)
Barry W Hancock, Jane Cook, Stacey Killick, Laura Ellis, Sarah Gillett, John Tidy, Initial presenting features in gestational trophoblastic neoplasia: does a decade make a difference? Journal of Reproductive Medicine. ,vol. 57, pp. 279- 282 ,(2012)
Audrey P Garrett, Ross S Berkowitz, Donald P Goldstein, Elizabeth O Garner, Methotrexate infusion and folinic acid as primary therapy for nonmetastatic and low-risk metastatic gestational trophoblastic tumors. 15 years of experience. Journal of Reproductive Medicine. ,vol. 47, pp. 355- 362 ,(2002)
Colleen M. Feltmate, Adam J. Wolfberg, Whitfield B. Growdon, Ross S. Berkowitz, Ellice S. Lieberman, Manuel E. Chinchilla, Donald P. Goldstein, Low-risk gestational trophoblastic neoplasia and methotrexate resistance: predictors of response to treatment with actinomycin D and need for combination chemotherapy. Journal of Reproductive Medicine. ,vol. 55, pp. 279- 284 ,(2010)
Ernest I. Kohorn, Negotiating a staging and risk factor scoring system for gestational trophoblastic neoplasia. A progress report. Journal of Reproductive Medicine. ,vol. 47, pp. 445- 450 ,(2002)
Persistent gestational trophoblastic disease: Results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease British Journal of Cancer. ,vol. 82, pp. 1547- 1552 ,(2000) , 10.1054/BJOC.2000.1176
Anca C. Ansink, Christine A. R. Lok, Leon F. A. G. Massuger, Mariëlle Donker, Mart M. Calff, Psychologic impact of follow-up after low-risk gestational trophoblastic disease. Journal of Reproductive Medicine. ,vol. 56, pp. 47- 52 ,(2011)
Allan Covens, Virginia L. Filiaci, Robert A. Burger, Raymond Osborne, M. Dwight Chen, Phase II trial of pulse dactinomycin as salvage therapy for failed low-risk gestational trophoblastic neoplasia Cancer. ,vol. 107, pp. 1280- 1286 ,(2006) , 10.1002/CNCR.22118